Most Read Articles
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Yesterday
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Migraine drug may impair mental alertness

06 Oct 2020

The centrally penetrant, selective serotonin 1F (5‐HT1F) receptor agonist lasmiditan appears to adversely affect driving performance at 1.5 hours postdose, but this effect disappears after 8 hours, as shown in a crossover trial.

Healthy adults were enrolled in two randomized crossover studies. Each study included an active control to establish the sensitivity of detecting residual sedation and resulting driving impairment. The first study included 90 participants and tested lasmiditan (50, 100, and 200 mg), alprazolam (1 mg), and placebo at 1.5 hours postdose. Sixty-eight individuals participated in the second study that tested lasmiditan (100 and 200 mg), diphenhydramine (50 mg, administered 2 hours prior to evaluation), and placebo at 8, 12, and 24 hours postdose.

Driving performance was assessed using a validated 100-km driving simulator, with the primary endpoint being standard deviation of lateral position (SDLP), a measure of lane position control. Blood samples were obtained pre‐ and post-dose to measure lasmiditan plasma concentrations. Assay sensitivity was confirmed by increased SDLP for active comparators at 1.5‐ and 8‐hour time points.

At 1.5 hours after dosing, driving performance was significantly impaired with lasmiditan doses than with placebo. But this difference disappeared at the 8-hour time point. Driving impairment was concentration‐dependent at 1.5 hours but not at 8 hours.

Commonly reported adverse events were related to central nervous system and mild‐to‐moderate in severity.

In light of the findings, the researchers warned patients taking lasmiditan against engaging in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after each dosing.

Editor's Recommendations
Most Read Articles
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Yesterday
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).